The generalized anxiety disorder (GAD) treatment market is expected to experience significant growth across major markets during the forecast period of 2026-2036, driven by rising prevalence of the disease, advances in diagnostic tools, and innovative emerging therapies. The United States accounted for the largest GAD treatment market size in 2025 compared to the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Among adults with GAD in the US, 32.3% experience severe effects on daily functioning, 44.6% have moderate effects, and 23.1% have mild effects.
Rising prevalence of GAD is being fueled by sustained exposure to psychosocial stressors, urbanization, lifestyle changes, economic uncertainty, social isolation, and population growth. Improved diagnostic tools and standardized criteria—including DSM-5—are enabling earlier and more accurate detection. Primary care settings are increasingly equipped to screen for anxiety, leading to more referrals and treatment initiations. Telemedicine and digital health services have expanded access to care, particularly in underserved regions, with digital therapeutic platforms and online cognitive behavioral therapy (CBT) tools enhancing treatment engagement and continuity.
Current treatment typically relies on SSRIs or SNRIs in initial therapy, with medications such as paroxetine, escitalopram, sertraline, and fluoxetine proving effective for easing persistent tension and apprehension. However, many current therapies have safety concerns and slow onset of action. Emerging candidates under development include DT120 ODT (LSD D-Tartrate) by Definium Therapeutics, Ulotaront (SEP-363856) by Sumitomo Pharma and Otsuka, HLP004 by Helus Pharma, ITI-1284 by Intra-Cellular Therapies, and ABBV-932 by AbbVie, which is being developed collaboratively with Gedeon Richter. In January 2026, MindMed rebranded to Definium Therapeutics and announced multiple anticipated Phase III milestones in GAD for 2026, with topline data from two pivotal Phase III studies expected in the second quarter and second half of 2026.
Gender and Epidemiology
In the UK, GAD is more prevalent in women than men, with around two-thirds of those diagnosed being female. The epidemiology analysis covers the 2022-2036 period, segmented by total prevalent cases, diagnosed cases, gender-specific and age-specific cases, and severity-specific diagnosed cases across leading markets.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.prnewswire.com/news-releases/generalized-anxiety-disorder-market-forecast-shows-strong-cagr-during-the-forecast-period-20262036-driven-by-innovative-therapies—delveinsight-302789866.html